New clinical trial studies drug combination for recurring ovarian cancer

Ovarian cancer

Ovarian tumor microenvironment
Photo credit: NCI Visuals Online

Women with recurrent ovarian cancer who have had at least three prior therapies may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Cancers of the ovaries, fallopian tubes and primary peritoneum are the fifth leading cause of cancer death in women in the U.S. and are often found at advanced stages. Jung-Min Lee, M.D., of the Women’s Malignancies Branch is leading a study of the effectiveness of an investigational drug combination of cediranib and olaparib. Use of cediranib intends to see whether reducing the supply of oxygen to the cancer cells can make the cancer shrink or slow its growth. Olaparib is an inhibitor of PARP, an enzyme found in the cells of your body. When DNA is damaged in normal cells, PARP helps to repair the damage.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: 04/2018